Lili Cheng Qi Song Mengke Liu Yan Wang Hongmei Yi Ying Qian Pengpeng Xu Shu Cheng Chaofu Wang Li Wang Weili Zhao
10.3389/fimmu.2021.702593
Front Immunol
2021 Jul 12;12:702593.
epstein-barr virus immune checkpoint inhibitor lenalidomide plasmablastic lymphoma tislelizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/34322131/
Antibodies, Monoclonal, Humanized / administration & dosage Antineoplastic Combined Chemotherapy Protocols / therapeutic use Lenalidomide / administration & dosage Plasmablastic Lymphoma / drug therapy
Antibodies, Monoclonal, Humanized / administration & dosage Antineoplastic Combined Chemotherapy Protocols / therapeutic use Lenalidomide / administration & dosage Plasmablastic Lymphoma / drug therapy Case Reports Research Support, Non-U.S. Gov't Aged Female Humans Antibodies, Monoclonal, Humanized tislelizumab Lenalidomide
PMC8312258
34322131
Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
2021